DoD Reconstructive Transplant, Advanced Technology Development Award | HT942524RTRPATDA

Opportunity Information: Apply for HT942524RTRPATDA

The FY24 DoD Reconstructive Transplant Research Program (RTRP) Advanced Technology Development Award is a grant opportunity from the U.S. Army Medical Research Acquisition Activity (USAMRAA) designed to push promising reconstructive transplantation work past the early discovery stage and closer to real-world use. The core purpose is translation: turning strong preclinical findings into tangible products and deliverables that can ultimately improve care in reconstructive transplantation, including vascularized composite allotransplantation (VCA) such as hand or face transplantation. Projects can focus on developing "materiel" products like drugs, biologics, or medical devices, as well as knowledge-based products like technical reports or clinical practice guidelines that directly inform clinical and operational decision-making and support evidence-based updates to standard of care.

The program places heavy emphasis on rigor, feasibility, and a clear pathway toward the next development milestone. Applications are expected to present a well-described, well-integrated study design that supports reproducibility and practical translation. When appropriate, proposals should include a statistical plan and power analysis, and they should show how the work will mature the product to be ready for the next phase after the award ends. If model systems are used, they must be relevant and appropriate to VCA. A key eligibility expectation is that applicants already have proof-of-concept data or a prototype or preliminary version of the proposed product. In other words, this award is meant to accelerate something that already has credible early evidence, not to fund purely exploratory ideas without preliminary support.

Military relevance is central. Proposed projects must address at least one of the FY24 focus areas for this mechanism (as defined in the full announcement) and must be responsive to the health care needs of military Service Members and/or Veterans recovering from traumatic injury, along with their family members, caregivers, and clinicians; benefits to the broader public are also part of the mission. Collaboration with Department of Defense and Department of Veterans Affairs researchers or clinicians is encouraged because it can provide access to unique expertise, infrastructure, and populations, but it is not mandatory. If a project depends on special resources, databases, or access to unique populations, the application must explain how access is secured at submission and how it will be maintained throughout the project.

A required element is a post-award Transition Plan that explains what happens after the grant period if the work succeeds. This plan is expected to identify plausible funding sources and resources for the next step (for example, moving toward clinical trials or preparing for delivery to military or civilian markets) and to include an appropriate regulatory strategy when relevant, such as planning for FDA-related requirements for a drug, device, or biologic. The announcement also explicitly allows applicants to leverage advances from solid organ transplantation and test them in a VCA setting, as long as the rationale is clear (for example, explaining why VCA biology might differ, why confirmation in VCA is necessary, or how VCA testing could reveal new mechanisms).

The opportunity also highlights the Department of Defense interest in advancing womens health research and innovation. Applicants are encouraged to consider how reconstructive transplantation may affect women uniquely, disproportionately, or differently than men, and to incorporate sex as a biological variable when appropriate. The intent is that findings should be connected to improving womens health outcomes or expanding knowledge relevant to womens health in the context of reconstructive transplantation.

In terms of project structure, the award allows either a single-PI application or a Multiple Principal Investigator option with up to four PIs. Under the multi-PI approach, one person serves as the Initiating PI and handles most submission and administrative responsibilities, while the other Partnering PIs contribute substantially to the science and execution. If funded, each PI is named on a separate award to their organization, with separate reporting and compliance obligations. The program also stresses rigorous experimental design practices aligned with widely recognized standards for transparent reporting and reproducibility, including principles like randomization, blinding, sample-size estimation, and clear data handling procedures.

A notable restriction is that clinical trials are not allowed under this funding opportunity. The announcement uses the federal definition of a clinical trial (45 CFR 46.102), meaning studies that prospectively assign human subjects to interventions to measure effects on health outcomes are not permitted. However, clinical research is allowed if it is observational in nature or otherwise does not evaluate safety, effectiveness, or efficacy outcomes of an intervention. Allowed examples include studies of mechanisms of disease, biomarker or imaging diagnostics, health disparities research, technology development that is not testing intervention outcomes, epidemiologic and behavioral studies that are not intervention-effect studies, and certain outcomes or health services research approaches. The program also notes that awardees may be invited to present progress at annual virtual In-Progress Review meetings.

Practically speaking, this is a competitive, mid-sized translational funding mechanism. The anticipated budget cap is up to $1.0 million in total costs for the full period of performance for single-PI applications and up to $1.5 million for applications using the Multiple PI option. The program expects to allocate about $3.5 million total to make roughly three awards, with actual funding dependent on federal funds availability and application quality through peer and programmatic review. Awards are planned to be issued no later than September 30, 2025. The closing date listed for applications is October 23, 2024, and the funding instrument is a grant under 31 USC 6304. The opportunity is listed under CFDA 12.420, with unrestricted eligibility, meaning a wide range of applicant organizations may apply if they can meet the program requirements and successfully propose a rigorous, military-relevant translational project in reconstructive transplantation.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Reconstructive Transplant, Advanced Technology Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-06-27.
• Applicants must submit their applications by 2024-10-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524RTRPATDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: